Abstract: Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated transcription factors that govern lipid and glucose homeostasis playing a central role in cardiovascular disease, obesity, and diabetes. These receptors show a high degree of stereoselectivity towards several classes of drugs. This review provides an overview of most papers reporting the influence of stereochemistry on PPAR activation. Some cases in which chirality is a crucial point in determining the PPAR binding mode are reviewed and discussed with the aim to show how enantiomeric recognition originates at the molecular level. The structural characterization by crystallographic methods of complexes formed by PPARs with their ligands turns out to be an essential tool to explain receptor stereoselectivity.
INTRODUCTION
Peroxisome Proliferator-Activated Receptors (PPARs) are ligand-activated transcription factors belonging to the nuclear hormone receptor superfamily [1] . PPARs are lipid sensors capable of adapting gene expression to integrate various lipid signals coming from intracellular signaling pathways, from inter-organ crosstalk or even from the diet [2] . Given their partially overlapping yet specific expression patterns, the three receptors cooperate to efficiently regulate metabolic functions [3] as well as other cellular processes such as proliferation, differentiation or apoptosis that are essential to the fate of the tissues and organs in which they are expressed [4, 5] . Three isotypes of human PPAR, commonly designated PPAR , PPAR and PPAR have been characterized, showing distinct tissue distributions, physiological roles and ligand specificity [6] . PPAR is found in liver, kidney, heart, and skeletal muscle. It is important for the uptake and oxidation of fatty acids and lipoprotein metabolism and is the molecular target for the fibrates (e.g., fenofibrate and gemfibrozil), a class of drugs that lower plasma triglycerides and increase HDL cholesterol levels in humans [7, 8] . PPAR is expressed in fat, large intestine, and macrophages and plays an important role in regulating plasma glucose. It is the receptor of the well-known antidiabetic insulin sensitizers drugs belonging to the thiazolidinedione (TZD) class such as rosiglitazone and pioglitazone [9] . The function of PPAR is still not fully understood but recent evidence suggests that this ubiquitously expressed PPAR isoform has pleiotropic actions that may govern diverse physiological processes, including the regulation of lipid and lipoprotein metabolism [10, 11] , insulin sensitivity [12] , cardiac function [13] , epidermal biology [14] , neuro-*Address correspondence to this author at the Dipartimento FarmacoChimico, Università degli Studi di Bari "A. Moro", via Orabona 4, 70126 Bari, Italia; Tel: +39 080-5442798; Fax: +39 080-5442231; E-mail: floiodice@farmchim.uniba.it.
protection [15] , and gastrointestinal tract function and disease [16] . To date, however, no PPAR agonist has been fully developed and the clinical potential of targeting this isotype remains to be clearly determined.
As ligand-dependent receptors, PPARs form heterodimers with the Retinoid X Receptor (RXR) and adopt an active conformation in the presence of an agonist [17, 18] . Natural ligands of PPARs include fatty acids and eicosanoids. Additional co-activator proteins are recruited to create a complex that binds to Peroxisome Proliferator Response Elements (PPRE) in target genes and stimulates their expression. The overall structure of the ligand binding domain (LBD) is common to all three isotypes of PPAR. The molecules fold into a single domain that contains a bundle of 13 helices and a small four-stranded -sheet. The ligand binding site is a very large cavity within the protein with a total volume of 1300 to 1400 Å 3 , which is substantially larger than those found in other nuclear receptors. It is enclosed by helices H2', H3, H4, H5, H7, H10/H11, H12, and -strands S3 and S4. The cavity is Y-shaped and can be divided into three arms. Arm I, extending toward the activation function-2 (AF2) of helix H12, consists of mainly polar residues. Arm II, situated between helix H3 and the -sheet, is mainly hydrophobic, which is not surprising given the hydrophobic nature of the natural ligands. The entrance region of the ligand-binding pocket (arm III) is essentially composed of polar residues and its shape, differently from arm I and arm II, is conserved. Therefore, the subtype specificity of PPAR agonists depends on the shape of these two arms. Especially, the shape of arm I of PPAR is narrower in the area next to the AF2 helix than the corresponding arm of the PPAR and PPAR pocket [19] [20] [21] [22] .
The large ligand-binding pocket of PPAR is able to bind a multitude of fatty acids and synthetic ligands. However, most of the current PPAR agonists share several common elements: an acidic head group connected to an aromatic ring through a short linker, and a second linker connecting the aromatic ring to a cyclic tail represented by either an aromatic or an aliphatic ring system which in general contains a hydrogen bond acceptor. The linkers can also contain additional substituents. Information gained from studying protein-ligand X-ray crystal structures of all three PPAR-LBD isoforms, has provided growing insight into the factors controlling receptor binding and functional activation as well as isoform selectivity [19, 20, [23] [24] [25] . In all three isoforms, the ligands occupy a large, curved binding pocket adopting a common binding mode for PPAR agonists. The acidic head group, represented so far by carboxylic acids and 2,4-thiazolidinediones, is involved in up to four hydrogen bonds with the receptor. This head group, by anchoring the flexible C-terminal transactivation helix (AF2 helix), is crucial for PPAR activation and successful coactivator binding. The central aromatic moiety is located in a hydrophobic protein environment, while the cyclic tail region is partly solvent exposed and tolerates more polar and diverse substituents.
Stereochemistry is of fundamental importance in PPAR molecular recognition. These receptors, in fact, show a high degree of stereoselectivity towards several classes of drugs. In particular, PPAR activity is strongly affected by the presence of a stereogenic center close to the acidic function which, therefore, plays a crucial role in determining the PPAR binding mode. Drugs with this structural feature represent the main part of chiral PPAR ligands. In this review they are described and discussed with the aim to show how enantiomeric recognition originates at the molecular level. The structural characterization by crystallographic methods of complexes formed by PPARs with their ligands turns out to be an essential tool to explain receptor stereoselectivity.
Thiazolidinediones (TZDs)
This class of drugs, also called "glitazones", was approved by the Food and Drug Administration (FDA) for the treatment of type 2 diabetes in the late 1990s. These agents are subtype selective, high affinity agonists for PPAR and correct hyperglycemia by enhancing the insulin sensitivity of adipose, hepatic and skeletal muscle tissues [26] [27] [28] . The general structure of TZD-class PPAR agonists is characterized by the presence of the 2,4-thiazolidinedione structural motif. Table 1 contains a listing of the well-known "classical" TZDs ciglitazone (1), troglitazone (2), rosiglitazone (3), pioglitazone (4), darglitazone (5), englitazone (8), netoglitazone (9) , and the more recent and promising rivoglitazone (6) and balaglitazone (7) which are now undergoing Phase III clinical trials [29] [30] [31] . Pioglitazone (Actos) and rosiglitazone (Avandia) are currently marketed agents for the treatment of type 2 diabetes [32] .
The TZDs contain a chiral centre at C-5 of the heterocyclic acid group, but have been developed as racemates since they undergo racemization under physiological conditions [33] . Using a PPAR binding assay, however, it has been shown that only the S enantiomer of TZDs binds to the receptor with high affinity [34] . The X-ray crystal structure of the PPAR -LBD complexed with the S isomer of rosiglitazone (3) shows that the ligand binds in a U-shaped conformation and the thiazolidinedione head group is engaged in a network of four hydrogen bonds with Ser-289 of helix 3, As this last residue belongs to a helix of the liganddependent activation function AF2, its interaction with the nitrogen of the TZD group is critical for transcriptional activation [35] . Considering the high structural similarity in this class, one can safely assume that the thiazolidinedione of all the glitazones plays the same role as for the co-crystallized rosiglitazone. The correct PPAR binding mode for glita-zones, therefore, is steered by the appropriate stereochemistry of this chiral carbon, whereas the possible presence of differently located stereogenic centers results in a less pronounced eudismic ratio. As an example, the stereochemistry at the chromane stereocenter of englitazone (8) has so little influence on its hypoglycemic activity [36] that the search for new analogs with restricted conformational flexibility of the alkoxy chain linking the central phenyl ring and the terminal ring led to the development of cyclic compounds containing non-stereogenic carbon at that site like in the series of benzofuran-and benzoxazole-based structures [37] .
An extensive research has been made in the last decade for new and effective PPAR ligands with additional benefits and/or fewer undesirable effects (weight gain, fluid retention, and increased risk of cardiac failure) compared to the currently marketed glitazones. For this purpose, a number of research groups have reported on cyclic bioisosteric replacements of the 2,4-thiazolidinedione head group. Among these derivatives, a new class of oxazolidinediones was developed which still retained potent antihyperglycemic activity due to the potent agonistic activity towards PPAR . Surprisingly, the (R)-2,4-oxazolidinedione analogues (10) and (11) shown in Fig. (1) were more potent antidiabetic agents in vivo and also more potent transcriptional activators in vitro at PPAR than their corresponding S enantiomers [38] . This suggests that these oxazolidinediones are less prone to racemization than thiazolidinediones, a behaviour that is probably due to the different stabilization of the carbanions to heteroatoms as previously reported for chiral thioanalogues of clofibric acid [39] . Furthermore, this was the first example of PPAR agonists with a chiral fivemembered acidic heterocycle in which the more active enantiomer is the R isomer. More recently, researchers at Merck reported on the novel oxazolidinedione derivative (12) with highly selective PPAR partial agonist activity. Also in this case, the R enantiomer was found to be more active of the corresponding S isomer [Liu, W. G. et al. Benzimidazolones: a new class of PPAR gamma selective modulators. 235th ACS National Meeting, New Orleans, April 6-10, 2008, Abstract MEDI 332]. No explanation was given for this difference between the thiazolidinediones and oxazolidinediones and no X-ray crystal structure of the PPAR complexed with an oxazolidinedione has been reported in the literature or in the Protein Data Bank so far.
L-Tyrosine Derivatives
These compounds were designed by replacing the thiazolidinedione ring of glitazones with a carboxylic group and by introducing an amine function on alpha carbon while keeping the para-hydroxybenzyl moiety intact. The first reports of a series of these derivatives, described as potent and selective PPAR agonists, appeared in 1998 [40] [41] [42] . Within this series, the S enantiomers, synthesized from naturallyoccurring L-tyrosine, displayed greater binding affinity and functional activity at PPAR than the corresponding R enantiomers, in agreement with the stereochemistry of binding reported for the TZDs. These data suggest that the facile racemization seen with the TZD class does not occur in this series whose most representative compounds (13) (14) (15) are reported in Table 2 .
These ligands showed a marked increase in functional potency and affinity for PPAR receptors when compared to the corresponding TZD antidiabetic agents. This difference can be explained by the additional interactions between the receptor and the bulky substituent of the tyrosine amino group. The X-ray crystallography of PPAR /farglitazar (13) complex, in fact, reveals that the carboxylic moiety of 13 forms hydrogen bonds with the same four residues (His-449, Tyr-473, His-323, Ser-289) that interact with the TZD head group of rosiglitazone (3). However, both phenyloxazole tail and -aminobenzophenone group of 13 occupy considerably deeper positions into the hydrophobic pocket formed by helices 6 and 7 and the so-called "benzophenone pocket" formed by helices 3, 7 and 10, respectively, making additional hydrophobic interactions that are not available to any molecules of the TZD class [43] .
A similar binding mode has been reported for the ligand GW409544 (16), a close structural analogue of 13 that lacks three carbon atoms on the proximal phenyl ring of the benzophenone moiety. Farglitazar (13) , however, is a potent activator of PPAR showing 1000-fold selectivity over PPAR . In contrast, 16 is one of the most potent dual PPAR / agonists with < 10-fold difference between its PPAR and PPAR activity. The crystal structure of the PPAR /16 complex shows that the acidic head group of the ligand forms hydrogen bonds with Tyr-314, Tyr-464, Ser-280, and His-440. Because of the larger steric size of Tyr-314 in PPAR compared with His-323 in PPAR , 16 occupies a position in which it lies 1.5 Å deeper into the PPAR ligand binding pocket than the position of 13 in the PPAR pocket. Farglitazar (13) can not shift in the PPAR pocket because of a steric clash with Phe-273, which caps the benzophenone pocket adjacent to the AF2 helix. Remarkably, the three carbon atoms, which were removed from 13 to generate 16, are responsible for this unfavorable steric interaction [44] . The search for drugs acting on different PPAR isotypes has basically started with the discovery of 16. Combination therapy, in fact, may have synergistic and wider therapeutic effects improving both glucose and lipid metabolism of patients suffering from type 2 diabetes as confirmed by a recent study on the metabolic parameters of patients concomitantly treated with PPAR and PPAR agonists [45] . Two novel Ltyrosine-based PPAR / dual agonists, chiglitazar (17) and C333H (18) , were conceived starting from 13 by replacement of 2-phenyloxazole moiety with carbazole or benzophenone with 2-furanacryloyl group, respectively. These agents, which were reported to improve insulin-sensitizing and hypolipidemic activity, are currently being investigated for the treatment of type 2 diabetes [46, 47] .
As an extension of their L-tyrosine-based series of PPAR ligands, GlaxoSmithKline Group designed and synthesized new molecules with reduced molecular weight compared to the first generation compounds. The basicity of the nitrogen atom to the carboxylate group plays a key role in modulating potency at PPAR , with analogues having reduced nitrogen basicity demonstrating the greater PPAR potency. Within this series, the pyrrole derivative (19) , shown in Fig. (3) , displayed the highest potency and selectivity for PPAR over PPAR in both binding and functional assays [48] . More recently, Pfizer Group employed the same template for the investigation of the effects resulting from modifications in the linker between the tyrosine phenyl ring and the lipophilic tail. The replacement of the ether moiety by acetylene-, ethylene-, propyl-, or nitrogen-derived linkers led to changes in the binding and activation of PPAR and PPAR with the most notable effects observed for PPAR when the ether linker was replaced with carbon-based linkers. Compounds possessing suitable profiles were evaluated in vivo in two different animal models of type 2 diabetes. The propylene derivative (20) and the propyl derivative (21) demonstrated robust antihyperglycemic activity; 21 produced also a significant reduction of triglycerides, insulin, and free fatty acid levels [49] . The ensuing replacement of the pyrrole moiety of 21 with 1,2,3-triazol-2-yl ring led to 22 with an approximately 10-fold increase in potency for activation of both PPAR and PPAR [50] . The effects of stereochemistry at the position of these three compounds as well as that of pyrrole (19) were investigated preparing the corresponding R enantiomers. A higher agonist activity of S enantiomers for both PPAR and PPAR subtypes in transactivation assay was found consistently with the enantioselectivity of the first generation tyrosine-based compounds. In order to better rationalize the difference in potency of 21 and 22, the Fig. (2) . L-tyrosine analogues with PPAR / dual agonist activity. structure of their complexes with PPAR -LBD were solved and superimposed onto the co-crystal structure of the potent, full agonists farglitazar (13) and GW409544 (16) complexed with the PPAR -LBD and the PPAR -LBD, respectively [49, 50] . All four agonists form a network of hydrogen bond interactions extending from the carboxylic group of the agonists to the Tyr-473, His-323, His-449 and Ser-289 residues (Tyr-464, Tyr-314, His-440 and Ser-280 in PPAR ) adjacent to the AF2 helix. In addition, all the compounds appear to position their 5-methyl-2-phenyloxazole tails in the same hydrophobic region. However, both 13 and 16 contain an ether moiety in the linker segment, while 21 and 22 contain a hydrophobic methylene. The differences in potency observed between 21 and the ether linker containing agonists are likely due in part to the loss of a hydrogen-bond interaction between the ether oxygen and the conserved Cys thiol (Cys-276 in PPAR and Cys-285 in PPAR ). The increased potency of 22, instead, is probably due to a new interaction that is not possible to obtain with 21. In fact, the formation of an additional hydrogen bond between N-2 of the triazole ring and the imidazole residue of His-449 in PPAR was observed. Molecular modeling studies allowed to hypothesize that a similar hydrogen bond could take place also with His-440 of PPAR .
Recently, a new series of conformationally constrained L-tyrosine derivatives was synthesized employing the structure of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid as a template. Compound KY-021 (23) was identified as a novel selective PPAR agonist with potent antihyperglycemic and hypolipidemic activity and great potential as an efficacious and safe drug for diabetes. Also in this case, the corresponding R isomer showed much lower activity confirming that a correct orientation of the groups bound to the stereogenic center close to the acidic function plays a crucial role in determining the PPAR binding mode in cyclic as well as branched ligands [51] .
Another class of compounds which can be included among conformationally constrained L-tyrosine derivatives was disclosed from researchers at Bristol-Myers Squibb. They reported unique azetidinone acid-derived PPAR / dual agonists displaying variable selectivity for receptor subtypes depending on the side chain. These compounds contain two stereogenic centers and the preferred stereochemistry for binding and functional activity against PPAR and PPAR was shown to be S for both of them. The absolute configuration was established resolving the X-ray co-crystal structure of the most interesting ligand BMS630717 (24) complexed with PPAR . Therefore, by analogy to 24, the 3S,4S stereochemistry was assigned to the more active enantiomers of other pairs of the series. The corresponding trans isomers (3S,4R) displayed significantly poorer activities against both PPAR and PPAR . In the crystal complex between the PPAR -LBD and the azetidinone derivative (24), the ligand is wrapped around H3 with its extremities approaching, respectively, the -sheet region from one side and helix 11 from the other side. The terminal phenyl methyl ether of the ligand forces the side-chain of Phe-273 to a folded conformation that allows the accommodation of its terminal end in a new region of the LBD. The polar head of the ligand makes the same canonical network of H-bonds with Tyr-464, Tyr-314, His-440 and Ser-280 with a shift of about 1.5 Å as reported above for GW409544 (16) . Looking at the crystal structure it is evident that the S configuration of both chiral C atoms is a strict requirement to allow the H-bond network of the carboxylate group and the accommodation of the terminal parts of the ligand in the LBD without steric hindrance. Despite its potent PPAR activity, however, compound (24) did not decrease plasma triglyceride levels, whereas exhibited significant plasma glucose lowering [52] .
A particular L-tyrosine analogue was obtained by substituting an ethyl amide group for the acid group of GW409544 (16) . This modification led to the potent PPAR antagonist GW6471 (25) . The crystal structure of a ternary complex containing the PPAR -LBD bound to 25 and a SMRT corepressor motif, shows that the ligand adopts a U-shaped configuration and wraps around Cys-276 of helix 3. The modified amide head group of 25 adopts a conformation that is no longer able to form a hydrogen bond with Tyr-464 on the AF2 helix. Instead, this larger head group extends into the space that is normally occupied by the side chain of Tyr-464, and blocks the AF2 helix from adopting the active position [53] . Surprisingly, neither reports have been published concerning the activity of 25 on PPAR nor the activity of the R isomer of this interesting pharmacological tool has been reported so far. GW6471 (25) had the expected profile of a classical antagonist of nuclear receptors, that is enhancing corepressor binding and diminishing coactivator binding. Interestingly, the two above-mentioned selective PPAR agonists GW1929 (14) and GW7845 (15) ( Table 2) showed a novel ligand profile; they, in fact, promoted the binding of coactivators and reduced the affinity for corepressor peptides on PPAR but, unlike classical agonists, increased the affinity for the same corepressor peptides on PPAR and, in the case of 15, also on PPAR . Structural studies suggest that the PPAR subtype differences in the size of the benzophenone pocket formed by helices 3, 7, and 10 and the AF2 loop are the molecular basis for the differential effects of these ligands on the binding of corepressors. This pocket in PPAR is somewhat smaller than in PPAR and significantly smaller in PPAR . Compounds (14) and (15), which have a bulky group on the tyrosine nitrogen, can occupy the ligand pocket of PPAR and PPAR but only with significant alteration of the pocket. These ligands push against the side chains of the helix AF2 linker region that in turn promote the displacement of the AF2 helix from its active position. However, differently from antagonist (25) , in 14 and 15 the bulky ligand substituent does not protrude out of the binding pocket and, therefore, would not sterically prevent the AF2 helix from assuming its active conformation such that they could also enhance the binding of coactivators. These unusual PPAR subtype dependent, mixed agonist/antagonist properties suggest that the biological effects of a ligand on a specific nuclear receptor depend not only on the intrinsic affinity of the ligand for the receptor but also on the coregulator context of the target cell. Compounds (14) and (15) would be expected to activate PPAR and PPAR when the coactivator/corepressor ratio is high and repress the receptors when the ratio is low [54] .
Recently, new atypical L-tyrosine-based ligands were reported from researchers at GSK who identified the uncommon PPAR inverse agonists GSK5737 (26) and GSK5775 (27) derived from farglitazar (13) . These compounds differentially recruited a set of 49 coregulatorderived peptides to PPAR -LBD showing markedly reduced, atypical coactivator binding and a neutral effect on corepressor binding. In a mature 3T3L1 adipocyte gene expression assay, these inverse agonists exhibited atypical activity on marker genes involved in fatty acid metabolism which were driven to expression levels below basal PPAR . The X-ray crystal structure of the simplest derivative of this series, compound (28), bound to PPAR -LBD shows that, differently from the farglitazar (13) carboxylate, the amide group of 28 merely approaches His-323 of helix 4 and Tyr-473 of AF2 helix without actually making any strong hydrogen bond. The AF2 helix is modestly unwound consistent with some destabilization of its activated conformation [55] .
-Alkyl--Phenylpropanoic Acid Derivatives
In an attempt to develop structurally new selective human PPAR agonists, Kyorin scientists selected KRP-297 (29), a unique glitazone with almost equal affinity towards both PPAR and PPAR subtypes, as a lead compound [56] . The replacement of the 2,4-thiazolidinedione ring of 29 with the carboxylic group led to the identification of -alkyl--phenylpropanoic acid derivatives with higher selectivity for PPAR over PPAR and PPAR [57] . Structure-activity relationship studies indicated that the molecular determinants of potency and selectivity towards PPAR subtypes were the nature of the substituent at the position of the carboxylic group, the distance between the acid head and the central benzene ring, the linker between the central benzene ring and the distal benzene ring, and the substituents at the distal hydrophobic tail. For KCL (30) , the most representative compound of this series, the effects on PPAR isoform of stereochemistry at the position of the carboxylic function were [26] [27] [28] investigated. The S isomer exhibited much higher affinity and functional activity than the corresponding R isomer in agreement with the stereoselectivity reported for the TZD and L-tyrosine derivatives. In normal rats, 30 lowered the serum levels of triglycerides, free fatty acids, and total cholesterol [57] . Interestingly, small manipulations of the structure of 30 led to analogues with modified pharmacological profile. By moving the amide carbonyl group close to the distal benzene ring and introducing a fluorine atom at the 2-position of the same ring, the PPAR / dual agonist TIPP-401 (31) was obtained. The replacement of the methoxy group of 31 with the longer n-butoxy allowed to develop the potent selective PPAR agonist TIPP-204 (32) . For both these new compounds, the corresponding stereoisomers were prepared and, as expected, a clear enantio-correlation was found. Again, S-31 and S-32 were much more active than the corresponding R isomers even though to a lesser extent for 32 compared to 31 [58] [59] [60] .
Compound (32) differs from 31 only in the length of the alkoxy group bound to the 4-position of the phenyl linker. In order to understand the PPAR selectivity of 32, molecular modeling studies were performed docking 31 into the PPAR and PPAR ligand binding domains. From the results, it was apparent that the methyl portion of the methoxy group of 31 was buried in a binding cavity of the PPAR -LBD composed of three amino acids, Val-298 in the -sheet 2, Leu-303 in the -sheet 3, and Ile-328 in the helix 7. In the case of PPAR , the corresponding binding cavity hosting the methyl portion of the methoxy group of 31 is composed of Met-325 in the -sheet 2, Met-330 in the -sheet 3, and Met-355 in the helix 7. The methylthioethyl side chain of Met is bulkier than those of Val, Leu, and Ile, and the cavity volume of PPAR was calculated to be threefold greater than the corresponding cavity of PPAR accounting for its capacity to accomodate, differently from PPAR , the n-butoxy group of 32. In particular, site-directed mutagenesis analysis clearly indicated that the PPAR selectivity of 32 can be largely attributed to favourable interactions between its nbutoxy group and Val-298 of PPAR . The transactivation activity of 32 on PPAR , in fact, greatly decreased (~30 times) in the case of the Val298Met mutant. In order to understand in detail why Val-298 is important for 32, the X-ray crystal structure of this ligand complexed with the PPAR -LBD was solved. The hydrophobic tail of the 2-fluoro-4-(trifluoromethyl)phenyl group is positioned in the pocket formed by helix 2', helix 3, helix 6, and the -sheets, as predicted by the modeling studies. The carboxylate group of 32 forms H-bond networks with Thr-253 in helix 3, His-287 in helix 5, His-413 in helix 10, and Tyr-437 in the AF2 helix. Notably, the n-butoxy group of 32 is positioned in the small cavity formed by Val-298 in -sheet 2, Leu-303 in -sheet 3, and Ile-328 in helix 7. Val-298 forms the floor, and Leu-303 and Ile-328 form the sides of the cavity, giving the shortest distance between Val-298 and the distal methyl group of 32. This may be the reason why the lengthening of the amino acid side chain, in the Val298Met mutation, causes a dramatic decrease in transactivation activity [61] .
More recently, an attempt to increase the PPAR activity of these -alkyl--phenylpropanoic acids was made with the aim to discover novel PPAR pan-agonists, that is ligands able to concomitantly activate all PPAR isoforms. Compounds with these characteristics are, nowadays, considered well-suited for the treatment of metabolic syndrome which is a combination of medical disorders increasing the risk of developing cardiovascular disease and diabetes. Simultaneous activation of all the PPARs might also reduce the occurrence of adverse side effects (weight gain, edema, cardiomegaly, anemia and bone fractures) which are often associated with the PPAR agonists currently used in therapy such as rosiglitazone and pioglitazone [62] . For this purpose, a further modification of the PPAR / dual agonist (31) was achieved by introducing bulky substituents at the 4-position of the distal benzene ring. The adamantyl derivative TIPP-703 (33), bearing also a n-propoxy group in place of methoxy on central benzene ring, proved to be a wellbalanced PPAR pan-agonist able to regulate the expression of genes involved in lipid and glucose homeostasis. The Xray crystal structure of PPAR /33 complex shows that the adamantyl group mainly contacts hydrophobic residues from helix H2' (Ile-241, Leu-247, Ala-250, and Val-255) and from the 3 strand (Val-332 and Ala-333) at the entrance of the ligand binding pocket. Furthermore, the propoxy group of 33 interacts with the three hydrophobic residues Met-325, Met-355, and Phe-359. In the PPAR /33 complex, the adamantyl group mainly interacts with Arg-280 and Ile-281 on the helix H3, whereas no significant interaction is observed between the propoxy group and the receptor. The structure of PPAR /33 complex is not known, however, binding features similar to that of PPAR /33 were supposed due to the higher similarity of PPAR to this receptor rather than PPAR [63] . Also in this case, 33 turned out to be more potent than its R isomer even though the eudismic ratio was lower than that observed for 31 [64] . Notably, the structural study revealed the enantioselectivity of the TIPP compounds. The ethyl groups bound to the stereogenic center of these S isomers are located at the deepest binding sites with the head carboxyl groups and contact the surrounding hydrophobic residues. When their R isomers approach the ligand-binding pocket, the ethyl groups may cause a steric clash with the surrounding residues, particularly those on the central parts of the H3 helix, even though some structural rearrangements could occur in both the proteins and ligands.
In the series of -alkyl--phenylpropanoic acids, the indanyl derivatives shown in Fig. (6) should be included. Bayer scientists used compound (34) as a prototype deriving from the combination of the indanylacetic head group with the substituted oxazole found in many PPAR ligands. They prepared a great number of compounds in which the following structural modifications were investigated: a) introduction of different groups at position of carboxylate; b) change of the heterocycle nucleus and chain length of the oxazolylethyl moiety; c) different substitution patterns of 2-phenyloxazole tail.
The activity of these compounds was evaluated by detemining how they affected the recruitment of the known coactivator CBP to PPAR and PPAR by performing FRET assay. The only variations which were successful in increasing potency compared to the prototype (34) were the substitution of the methyl group at position of carboxylate with ethyl and the presence of substituents on the phenyl bound to oxazole. A final consideration in these structures was the stereochemistry of the indanylacetic acid region in which two stereogenic centers are present. For the compounds (35-38) shown in Fig. (6) , the individual stereoisomers were separated by HPLC on chiral stationary phase and evaluated by FRET assay. A striking chiral effect was made clear by these studies. A strong preference at both PPAR subtypes for the S configuration at the carboxylic acid center was observed, whereas the R configuration at indanyl nucleus was slightly more favourable for PPAR activity. The R configuration at both stereogenic centers resulted to be particularly unfavourable. An oral administration in db/db mice of compound (2S, 3S)-36 caused a decrease in blood glucose and triglycerides levels with a significant increase of HDL [65] .
-Alkoxy--Phenylpropanoic Acid Derivatives
The presence of substituents at the position of the carboxylic group mimicking the thiazolidinedione acid head of glitazones had been already accomplished in the late 1990s. Scientists at Pfizer reported on a series of -thio-andalkoxy--phenylpropanoic acids exemplified by compounds (39) and (40) with excellent hypoglicemic effects. Although these analogues were not tested for PPAR activity, studies demonstrated that the in vivo activity in the -alkoxy series resided exclusively in the S enantiomers which is in agreement with the stereoselectivity of drugs mentioned earlier.
The same result was obtained in vitro by examining the ability to stimulate glucose uptake in a cell line. Instead, both isomers in the -thioacid series were equally active in vivo but not in vitro, suggesting that racemization takes place in vivo for these derivatives as previously reported for glitazones [66] . Fig. (7) . Examples of -thio-and -alkoxy--phenylpropanoic acids with hypoglicemic effects. Similar approach was used by the scientists from SmithKline Beecham who examined several -halo, -thio, -amino, -alkyl, and -alkoxy derivatives of -phenylpropanoic acid (41) . Within this series, the -alkoxy analogues were the most potent compounds showing excellent PPAR transactivation activity in good correlation with hypoglicemic effects in vivo. Again, their S enantiomers had higher affinity and potency than the corresponding R enantiomers. Rather surprisingly, however, the -methoxy member of this series failed to show any distinction in vivo between the two enantiomers. The equivalence as antidiabetic agents was attributed to a highly substrate dependent unidirectional stereoinversion of the R isomer similar to that well documented for non-steroidal anti-inflammatory drugs such as (R)-ibuprofen [67] [68] [69] [70] .
Scientists from GlaxoSmithKline reported on a series of phenyloxadiazole-substituted -isopropoxy-phenylpropanoic acids with potent dual agonist activity on PPAR and PPAR . Several of these compounds also exhibited partial agonist activity on PPAR . Interestingly, the resolution of the analogue (42) showed different levels of enantioselectivity on the three PPAR subtypes. PPAR and PPAR activity, in fact, resided mainly in the levo-isomer, whereas PPAR activity was retained in both enantiomers. The absolute configuration of the levo-isomer was assumed to be S based on the co-crystal structures of PPAR with related compounds [71] . In 2001 scientists at AstraZeneca disclosed the -ethoxy--phenylpropanoic acid PPAR / dual agonist tesaglitazar (43) which was reported to be about 10-fold more potent at PPAR than at PPAR . No data was shown for the corresponding R enantiomer. Tesaglitazar was the first ethoxypropanoic acid-based glitazar for which co-crystal stucture with PPAR and PPAR was released. The binding mode was reported to be very similar to that of the selective PPAR agonist farglitazar (13); however, due to the smallethoxy substituent, the carboxylate head group of 43 would be able to form a favourable hydrogen bonding network also into the ligand binding pocket of PPAR where Tyr-314, which is bulkier than its equivalent His-321 in PPAR , would act as a sterically discriminating residue [72] .
The -ethoxy--phenyl-propanoic acid moiety was chosen as a scaffold for the preparation of a series of novel derivatives in which different tricycle systems were introduced in the hydrophobic tail. Some potent PPAR / dual agonists were disclosed whose activity mainly resided in the S isomers. The investigation of the X-ray structure of PPAR complexed with two of these ligands, ragaglitazar (44) and its carbazole analogue (45), as well as docking studies of ragaglitazar into the binding pocket of PPAR , showed a binding mode very similar to that of tesaglitazar [73] [74] [75] .
Ragaglitazar was used as a structural template for the preparation of the N,N-diphenylamine derivative (46) lacking the oxygen atom between the two phenyl rings of the dibenzoxazine system. This modification caused a loss in both potency and efficacy towards PPAR and PPAR and no activation of PPAR . However, by substituting the amino group in 46 with a methine, the more planar lipophilic compound (47) was obtained which had equal potency on all three PPAR isoforms. The potency of 47 was improved by synthesizing the mono-and bis-substituted derivatives (48) ; for the mono-substituted analogues, activation data showed only minor potency and efficacy differences between E and Z geometric isomers [76] . Fig. (9) . -Ethoxy--phenyl-propanoic acids with PPAR / dual agonist activity. Fig. (10) . -Ethoxy--phenyl-propanoic acids obtained using ragaglitazar as a structural template.
Further modification of 47 gave the triple PPAR / / activators (49) and (50) which were used as starting points for the design of dimeric agonists, that is ligands containing two recognition units linked covalently through either a common group or through a spacer. The results showed that dimeric ligands had altered PPAR subtype profile compared to the monomeric counterparts, suggesting that the dimeric design concept can be used to fine tune the subtype selectivity of PPAR agonists. In an attempt to explain the different pharmacological profile between the dimeric ligands and their monomeric leads, crystallographic studies on PPAR complexed with compound (51) were conducted. This ligand, in fact, was more potent on PPAR than on PPAR and PPAR , whereas its monomeric counterparts (49) was more potent on PPAR . The X-ray structure shows that one-half of the ligand superimposes well with previously published (S)-2-ethoxy-3-(4-substituted-phenyl)propanoic acid derivatives and makes the earlier reported hydrogen bond interactions. The opposite half could not be unambiguously positioned indicating high flexibility. Modeling experiments were performed to predict the binding mode of this part of the ligand; the results suggest that part of the receptor subtype profile could be due to interactions with amino acid residues in the lipophilic pocket close to the re-ceptor surface. Surprisingly, the dimeric ligand (51) exhibited excellent pharmacokinetic properties despite breaking all the "rule of five" criteria [77, 79] . A further modification of compound (49) was achieved by removing the olefine methyl and the para-phenyl ring and introducing substituents in meta-positions of the resulting compound. Some potent and selective PPAR agonists were obtained with substituents having van der Waals volume around 260. Compound (52) displayed the highest PPAR selectivity with a potency ratio to PPAR and PPAR of 410 and 2000, respectively [79] . Fig. (11) . Examples of -ethoxy--phenyl-propanoic acids with different PPAR subtype selectivity profile.
Recently, scientists at Lilly reported on a series of (S)-2-methoxy-3-(4-substituted-phenyl)propanoic acids containing a bis-phenoxy group in the hydrophobic tail. Two derivatives, naveglitazar (53) and LSN862 (54) , were the first example of dual selective PPAR modulators (SPPARMs) acting as partial agonists on PPAR and PPAR subtypes. The SPPARM approach has recently attracted considerable attention in that proposes that diverse PPAR ligands, depending on their chemical structures, would bind in distinct manner to the LBD of PPARs inducing different levels of activation and distinct conformational changes of the receptor, leading to differential interactions with coactivators and corepressors. Structurally diverse modulators or partial agonists, therefore, are likely to elicit different pharmacological and toxicological effects depending on the context of tissue, i.e. abundance of cofactor proteins and target gene. This may enable uncoupling of the benefits of PPAR activation from the adverse effects associated with full agonism. Despite their partial agonist activity on PPAR and PPAR , 53 and 54 exhibited potent hypoglycemic activity and beneficial effects on lipid levels demonstrating that full agonist activity is not necessary to achieve potent and efficacious agents for the treatment of diabetes and dyslipidemias [80, 81] .
Scientists at Pfizer reported on a class of -alkoxy--pyridine-propanoic acids acting as potent dual agonists towards PPAR and PPAR . Within this series, binding affinity and functional and in vivo activities of some derivatives were evaluated on both racemates and enantiomeric forms showing, in one case, a remarkable eudismic ratio. For this ligand, the eutomer (55) was predicted to have the S configuration based on literature precedents [82, 83] . This claim, however, seems to be incautious if one considers that examples of reverse enantioselectivity are reported in the literature for PPAR agonists containing an oxygen atom directly bound to a tri-or tetra-substituted asymmetric carbon at position of the acid function [38, see also fibrates below]. Another class of novel PPAR / co-agonists was disclosed by scientists at Hoffmann-La Roche who reported the successful replacement of the central phenyl ring present in a large number of synthetic PPAR agonists with a 1,4-or 1,5-disubstituted indole scaffold, while maintaining thealkoxy-substituted propanoic acid head group. Only racemates were described, even though the Authors claimed that selected compounds were prepared and tested in optically pure form confirming that essentially all PPAR activity resided in the S enantiomers. The crystal structure of PPAR -LBD complexed with one of these isomers, compound (56) , was investigated showing a binding mode very similar to previously published PPAR complex structures suggesting that the N-methylene-substituted indole-5-yl-propanoic acid represents an excellent bioisosteric replacement of the known tyrosine-based scaffold [84] .
The same scientists at Hoffmann-La Roche also reported on a X-ray-guided design approach leading to a novel series of -ethoxy--phenyl-propanoic acids with high potency towards the PPAR and PPAR receptors and a good selectivity against PPAR . Side chain variations within this series allowed the adjustment of the PPAR / potency ratio ranging from equally balanced to -selective compounds. The influence of stereochemistry was assessed by preparing both enantiomers of compound (57) and, as described for other PPAR agonists, essentially all PPAR activity can be attributed to the S isomer. For further profiling, the S enantiomers of compounds (58) (59) (60) (61) , which possessed the desired PPAR / potency ratio equal to or greater than one, were synthesized as well. Their functional activity on the and receptor subtypes was higher, while the values were only slightly affected. In order to better understand the remarkably high selectivity of (S)-58, the X-ray complex structures of this ligand with PPAR and PPAR ligand binding domain were solved. The typical four strong hydrogen bonds between the ligand carboxylate and the Ser, His, and Tyr residues of PPAR and PPAR , respectively, could be identified. However, the overall number of interactions of the phenylthiazole moiety was significantly larger in PPAR compared to PPAR . In particular, Cys-275 (PPAR ), differently from Gly-284 (PPAR ), yielded three additional interactions with the terminal phenyl group. Moreover, the presence of a great number of sulfur-containing protein side chains in PPAR (Cys and Met) allowed the formation of more hydrophobic sulfur and in particolar sulfur-arene interactions which are known to be strongly attractive [85] . Fig. (13) . Examples of -alkoxy--pyridine-and -alkoxy--indole-propanoic acids with PPAR / dual agonist activity. Fig. (14) . Novel -ethoxy--phenyl-propanoic acids with balanced PPAR / dual agonist activity.
An extension of this work led to explore the potential of bicyclic cores in place of the central phenyl ring of these ligands. A close inspection of several X-ray structures revealed, in fact, that a simple phenyl ring does not optimally fit the cavity of PPAR receptor. The series of naphthalene and benzothiophene analogues (62) reported in Fig. (15) was, therefore, prepared and tested in vitro and in vivo. Most of the molecules turned out to be potent and balanced PPAR / co-agonists and, as could be anticipated, R isomers were almost inactive. No experimental evidence was reported for the assignment of absolute configuration even though the X-ray structure of one of the eutomers, compound (63), complexed with both PPAR and PPAR LBD showed a clear electron density for the bound ligand in the form of its S enantiomer. The overall shape of these complexes was very reminiscent of previously published PPAR and complex structures with the central benzothiophene linker that snugly fitted into the protein cavity as anticipated. Based on the highly promising data obtained in different animal models, 63 was selected as clinical candidate under the USAN name aleglitazar and it recently completed successfully clinical phase II studies [86] .
Very recently, the (S)-2-ethoxy-propanoic acid head group, which is a potent binding motif for the AF2 helix interface, has attracted the attention of many scientists in search for new PPAR / dual agonists. Researchers at Dong-A were particularly involved in this specific area. In 2007, they diclosed the series of thiocarbamate-based PPAR / dual agonists (64) containing a second stereogenic center. Interestingly, the agonist activity of these molecules sensitively changed according to the stereochemistry at the chiral benzylic carbon, particularly for PPAR . The S isomer of 65 was more potent than the corresponding R isomer for PPAR , while both exhibited similar activity for PPAR . On the contrary, the R isomer of compound (66) , showing the most potent activity for PPAR , was 10-fold more potent than the S isomer for PPAR . Docking studies provided an explanation in part for the stereochemistry/substituentdependent selectivity for the PPAR isotypes. The benzylthiocarbamoyl moiety of (S)-65 seems to fit well to the lipophilic region of the active site of PPAR , while the corresponding moiety of (R)-65 is forced from the stereochemistry to orient toward the hydrophilic region. The p-tertbutyl-benzyl group of 66, instead, appears to be too bulky to fit to the lipophilic pocket of PPAR ; subsequently, both R and S isomers are forced to orient this moiety toward the spacious hydrophilic pocket. As a result, the activities of (R)-65, (S)-66, and (R)-66 seem to be reduced by the inadequate orientations of their lipophilic moiety [87] . Fig. (15) . Naphthalene-and benzothiophene-based -alkoxy--phenylpropanoic acids with balanced dual PPAR / agonist activity.
More recently, the same scientists at Dong-A identified two other (S)-2-ethoxy-propanoic acids with different pharmacological profiles. For PAR-5359 (67), which was claimed to be the first compound with balanced activities for PPAR and PPAR in vivo as well in vitro, the utilization as a pharmacological tool in elucidating the complex roles of PPAR / dual agonists was suggested [88] . PAR-1622 (68), on the contrary, is a selective modulator of PPAR (SPPAR M) with excellent antihyperglycemic activity and a broader safety margin against fluid retention compared to rosiglitazone [89] . These findings confirmed that partial activators of PPAR may be a promising approach for developing new drugs for the treatment of type 2 diabetes.
In an attempt to identify dual PPAR / ligands with more beneficial biological activities than known dual agonists, a novel series of (S)-2-ethoxy-propanoic acids was prepared selecting tesaglitazar as the chemical lead. Chemical modifications focused on the oxyethyl chain between the two phenyl rings, which was replaced with rigid oxime ether (69) or isoxazoline ring (70) linkers. Most of the compounds possessing an oxime ether linker were more potent PPAR activators than tesaglitazar or even selective PPAR agonists. Whatever the linker, still the S isomers displayed higher activity on both PPAR and PPAR than corresponding enantiomers containing (R)-2-ethoxy-propanoic acid head group [90] . 
-Substituted Aryloxyacetic Acid Derivatives (Fibrates)
Fibrates are a class of triglyceride lowering agents that mediate their clinical effects through activation of PPAR . For several years, drugs such as clofibrate (71) , bezafibrate (72) and fenofibrate (73) have been broadly used for the clinical treatment of dyslipidemia and they still remain the therapy of choice for patients affected by severe hypertriglyceridemia. Stereochemistry of fibrate analogues bearing a stereogenic center at the position of carboxylate group strongly affects their pharmacological profile. The first report in this field dates back to 1997 when Rangwala et al. prepared and tested on PPAR a series of chiral analogues of clofibric acid, the active metabolite of clofibrate. Two of these derivatives, compounds (74) and (75), showed a high degree of stereoselectivity with the S isomers much more active than the corresponding R isomers [91] . Some years later, scientists at Merck used the scaffold of compound (75) to prepare a series of dual PPAR / agonists characterized by their balanced binding affinity for both receptors along with a "super" agonist activity towards PPAR and a weak or partial agonist activity against PPAR . The effect of the stereochemistry at the position of carboxylic group was examined and the results clearly showed that the binding and functional activity for both and receptor mainly resided in the S enantiomer. With the aim to explain the partial agonist response of these derivatives towards PPAR despite their relatively high binding affinity for the receptor, compound (76) was chosen to co-crystallize with PPAR -LBD as a binary complex and the structure obtained was superimposed on the co-crystal structure of PPAR / rosiglitazone. Compound (76) binds to the receptor with its carboxylic group forming the canonical hydrogen bonding network (Ser-289 of helix 3, His-323 of helix 4, His-449 of helix 11 and Tyr-473 of helix 12); the isoxazolone and the pisopropyl-substituted aromatic rings give interactions similar to those previously reported for nearly all of the PPAR /agonist complex structures. However, unlike rosiglitazone, no part of 76 extends past the Cys-285/Met-364 boundary. Overall, these results suggest that simply forming a direct link to helix 12, although necessary, is not sufficient for full agonism. In vivo evaluation of 76 showed excellent anti-hyperglycemic efficacy and hypolipidemic activity without provoking some typical PPAR -associated side effects [92, 93] .
Another interesting representative of -aryloxyphenylacetic acids is metaglidasen (77) which is currently in Phase II/III clinical development as an oral glucose-lowering agent for the treatment of type 2 diabetes. Metaglidasen is the levo-enantiomer of halofenate, a drug developed for lipid lowering that was tested clinically in the 1970s as a hypolipidemic and hypouricemic agent [94, 95] . Both halofenate and metaglidasen are prodrug esters that are rapidly and completely modified in vivo by non-specific serum esterases to the corresponding free acid forms. In vitro and in vivo preclinical studies revealed that metaglidasen behaves as a SPPAR M with antidiabetic and hypolipidemic activity similar to full agonists without causing some of the typical PPAR side effects of glitazones [96, 97] . The key amino acid Tyr-473, essential for the binding of full agonists to PPAR , is not required for metaglidasen activity as demonstrated by similar functional potency with wild-type and mutated Tyr473Ala PPAR [97] . These results were confirmed by solving the X-ray crystal structure of the metaglidasen acid metabolite bound to PPAR even though this structure has not been released yet.
Metaglidasen and halofenate show the same activity both in vitro and in vivo suggesting the lack of stereoselectivity from PPAR [97, 98] . This is surprising if one considers the high stereoselectivity exhibited from this receptor towardsaryloxy-phenylacetic acids with high structural similarity such as 75 and 76. The mainspring for the clinical development of metaglidasen in place of the more easily achievable halofenate seems to be its lower ability to inhibit cytochrome P450 2C9 (CYP2C9) compared to the corresponding dextroisomer which is about twenty-fold more active [99] . Differently from the similar analogues (75) and (76) no PPAR activity was detected for metaglidasen [96] ; its in vivo lipid lowering ability is therefore mediated by an alternative mechanism which is yet to be determined. Curiously, the only reference in which the absolute configuration of metaglidasen is reported to be R, even though in a somewhat unclear way, is a patent of 2007 [100] ; in all ensuing papers, however, metaglidasen is still considered as the levo-isomer of halofenate.
The scaffold of 2-phenoxy-2-phenyl acetic acid was used as a starting point for the preparation of a number of derivatives, represented by the general formula (78) reported in Fig. (18) , in which different substituents were introduced on both the aromatic rings and the phenyl was moved from the stereogenic center by introduction of one or more methylene units in some cases linked to the phenyl by an ether group [101] [102] [103] [104] [105] . Some potent PPAR full agonists were obtained with partial agonist activity against PPAR . These ligands generally showed a high degree of stereoselectivity, especially on PPAR , with the S isomers much more active than the corresponding R isomers. To rationalize the partial agonism activity of these compounds on PPAR , the X-ray structure of the PPAR /79 complex was solved. The canoni-cal intermolecular H-bonding network of carboxylate group with residues His-323, Tyr-473, His-449, and Ser-289 is still observed. However, differently from PPAR full agonists, this ligand induces a lower stabilization of H11 and increased stabilization of H3 through favorable interactions with Ser-289 and Gln-286, particularly. In addition, the rigid and straight diphenyl group of 79 induces a switching of the Phe-282 side chain from the extended conformation to a folded conformation rendering accessible a new region never sampled before by other ligands. This behaviour is similar to that reported above for the azetidinone compound (24) towards the Phe-273 of PPAR . The region is "L" shaped and the diphenyl group occupies the first branch corresponding to about 50% of its entire volume. The Authors proposed to name this branch "diphenyl pocket" in analogy with the "benzophenone pocket" [104] . The design of compounds (80) and (81) as well as the other ligands of the series was made with the aim to prepare analogues of 79 that could occupy the entire "diphenyl pocket" protruding toward H11 and H12. However, despite the greater flexibility of the diphenyl-methylene and diphenyl-ethylene moieties of 80 and 81, respectively, X-ray studies show that these groups occupy the same portion of the cavity as the diphenyl group of 79, between H3 and the Met-463 of the loop 11/12. The partial agonism of these compounds toward PPAR is in accordance with the hypothesis that ligands that better stabilize H3 rather than H11 and H12 lose the character of full agonists [105] . Interestingly, the same Authors also reported the crystal structure of PPAR bound to the less active R enantiomer of 79. X-ray studies show that, inside the cavity, this isomer occupies a different region with respect to 79, between H3 and the -sheet. In this way its polar head can not form the usual network of H-bonds with His-323, His-449, and Tyr-473, and it does not interact at all with H11 and H12. The carboxylate group forms one H-bond with Ser-342 NH of the -sheet and engages the charged Arg-288 residue of H3 in an electrostatic interaction. Obviously, the positioning of this isomer in a different region of the cavity leaves the Phe-282 side chain in its usual conformation [104] .
In search for new PPAR / dual agonists, scientists at Lilly designed the class of compounds (82) deriving from the fusion of the putative pharmacophores of the known PPAR and PPAR agonists. Analogues with high affinity binding and potent agonist activity on both receptors were identified. To address the impact of chirality, both enantiomers of some -methyl-substituted carboxylic acids, among which LY-510929 (83), were prepared and tested. The results showed that the S isomers had substantially better affinity and efficacy at both receptor subtypes than the R counterparts [106] . Equivalent results were obtained from scientists at Sankyo with the analogues (84) containing a pyridine-2-yl-phenyl moiety [107] .
With the aim to discover a new potent PPAR / dual agonist, scientists at Merck started from fibrates and, by forming a ring between the phenyl group and the alkyl substituent to the carboxylate moiety, prepared a series of chiral chromane-2-carboxylic acids. They assumed that it would be possible to preserve PPAR activity typical of fibrates and introduce PPAR activity due to the structural similarity of these "cyclized fibrates" with glitazones. In fact, the key functional groups of these two classes of compounds, namely the acidic head group and the phenyl group, were laid out in a very similar fashion. In effect, a systematic SAR study allowed to identify some potent PPAR / dual agonists. The influence of stereochemistry was also examined and chiral resolution was performed on the most potent compounds (85) and (86) . In this case, the R enantiomers clearly showed far superior activity compared to the corresponding S enantiomers. (R)-85 exhibited comparable antihyperglycemic activity to rosiglitazone and, in addition, lipid-lowering effects in different animal models [108] . The replacement of the p-fluoro-phenoxy group of (R)-86 with acyclic and cyclic aliphatic groups, led to highly potent and selective PPAR agonists. The (2R)-methyl-chromane derivative (87) , showing the most interesting pharmacological and pharmacokinetic profile, exhibited robust lowering of total cholesterol in two different animal models [109] . A novel class of PPAR agonists displaying very high potency and subtype selectivity as well as highly potent and efficacious hypolipidemic activity in animal models, was obtained from the same scientists preparing the series of 2,3-dihydrobenzofuran-2-carboxylic acids shown in Fig. (19) . The effects of chirality on the activity of these fivemembered "cyclized fibrates" were investigated by comparing the activity of the two pairs of enantiomers from the 2-ethyl-and 2-isopropyl-substituted derivatives (88) and (89) . Interestingly, it was found that (S)-88 and (R)-89 were about 400 times more potent than their respective isomers. This stereoselectivity was far superior compared to that previously reported for other PPAR ligands probably due to the additional conformational constraint imposed by the rigid cyclic structure [110] . It is to be noted that (S)-88 and (R)-89 only apparently have opposite absolute configurations. These isomers, in fact, have the same R group orientation, but different stereo designation due to priority change of the groups bound to the asymmetric carbon. In this regard, it is worthwhile underlining that, differently from structures reported above, in -substituted aryloxyacetic acids the typical structural determinants of PPAR ligands, represented by lipophylic tail, linker and aromatic ring, are bound to the stereogenic center through an oxygen atom in place of a ben-zylic methylene as shown in Fig. (20) . This means that in most cases an opposite priority of the groups bound to the chiral carbon occurs. Therefore, the investigation of the effects of stereochemistry for these chiral fibrates should reveal, by analogy with all the other structures previously examined, better activity for R enantiomers compared to the corresponding S isomers. Actually, the stereoselectivity shown from PPARs towards -substituted aryloxyacetic acids changes depending on type, size and number of substituents bound to the stereogenic center. From the data reported in the literature, it seems that R enantiomers are generally preferred when the chiral center is included into a conformationally constrained ring or is a tetrasubstituted asymmetric carbon. When steric constraints are less hampering, a reverse stereoselectivity occurs probably due to a different interaction of the phenoxylic oxygen that changes the preferred orientation of the ligand into the receptor hydrophobic pocket. It can not be ruled out, however, a wrong assignment, in some cases, of the absolute configuration to enantiomers. Fig. (19) . Examples of "cyclized" fibrates. A series of compounds supporting this assumption was reported from scientists at Merck. The selective PPAR agonist (90) displayed higher binding affinity and functional activity than the corresponding S isomer leading to the preparation of a number of analogues with the same absolute configuration. A systematic SAR study allowed to identify the optimized subtype selective PPAR agonist (91) showing excellent in vivo efficacy on dyslipidemia and additive cholesterol-lowering effect when co-administered with simvastatin [111] .
Another example of eudismic ratio favourable to R enantiomers is reported in Fig. (21) . All analogues (92) (93) (94) showed more than 10-fold higher PPAR activity than the corresponding S enantiomers. Lower activity and, interestingly, lack of stereoselectivity were observed towards / isoforms [112] .
Fig. (21).
Examples of PPAR agonists with eudismic ratio favourable to the R enantiomers.
A similar scaffold was used for the preparation of the two enantiomers of compound (95), a conformationally constrained analogue of the PPAR / dual agonist GW2331 (96) for which no experimental evidence of stereoselectivity has been reported. (R)-95 was able to fully activate both PPAR and PPAR , showing higher potency on PPAR . The S enantiomer displayed a lower efficacy toward PPAR and behaved as a partial agonist of this receptor subtype. A molecular explanation for their different behavior as full and partial agonists of PPAR was provided by showing the crystal structures of the complexes of these new ligands with PPAR -LBD. These model compounds were particularly suitable to study the mechanism of partial agonism, because they differ only for the switching of a methyl with an ethyl group on the asymmetric carbon atom, a small structural change that causes a significant difference in the pharmacological profile. Although helix 12 is in a similar conformation in both complexes, there are some important differences. In the crystal complex PPAR /(R)-95, the active conformation of H12 is stabilized by the canonical hydrogen bonds of both carboxylate oxygens of the ligand with the three residues His-323, His-449, and Tyr-473 involved in the receptor activation. The appropriate position of the Tyr-473 aromatic side chain is ensured by polarization interactions with Ile-472 and Leu-476 on one side and with Val-450 and Leu-453 on the other side. In addition, the methyl and ethyl groups bound to the asymmetric carbon form several favorable hydrophobic interactions with Leu-453 of H11, Leu-469 of H12, and Leu-465 of the loop 11/12. Thus, the potency of the R enantiomer is a direct consequence of a very effective stabilization of the helix 12, through hydrophobic and electrostatic interactions. The complex with the S enantiomer was solved after either 30-day or 6-hour soaking. In the former, a 1-Å shift of the ligand away from helix 12 is observed. This is probably caused by a steric clash between the ethyl group to the carboxylate group and the Gln-286 backbone. Even if the H12 conformation only slightly differs from that observed in the complex with the R enantiomer, its stability appears completely different. In fact, only one of the carboxylate oxygens of the ligand engages hydrogen bonds with the three residues His-323, His-449, and Tyr-473; moreover, the 1-Å shift of the ligand reduces the number of favorable hydrophobic contacts with helix 12 and the Tyr-473 aromatic ring adopts a different orientation, forming van der Waals interactions only with Leu-453 of H11. The Authors argued that this suboptimal conformation of helix 12 is probably inactive. In the structure from crystals soaked for 6 h, instead, the helix 12 is in the canonical transcriptionally active conformation. The presence of a steric hindrance between the ethyl group of the ligand and the backbone of H3 (Gln-286), however, forces the ligand to displace its position, weakening the hydrogen bond with Tyr-473. The two crystal structures with the S enantiomer, collected after different soaking times, offer two snapshots depicting different nuclear receptor conformations provoked by the binding of a partial agonist in the LBD and suggest the coexistence in solution of transcriptionally active and inactive forms [113] .
In an attempt to identify new and structurally diverse leads active on PPAR , Merck scientists prepared several series of new derivatives based on the indole core, a nucleus which was already present in a large number of PPAR agonists such as indomethacin [114] , nTZDpa [115] , and 2,3-disubstituted indole 5-acetic acids [116] . A SAR study led to potent selective PPAR modulators typified by the meta-(S)-lactate substituted 3-benzylic indole MRL-24 (97) [117] . This compound displayed excellent efficacy in rodent diabetes models, but, unfortunately, is metabolized via loss of the p-anisoyl group to a compound that was a potent inhibitor of CYP2C9. Thus, second generation N-benzyl-indole analogues (98) with improved metabolic profile were developed [118, 119] . Most compounds were prepared only as S isomers and turned out to be potent SPPAR Ms as well; for some lactates, the impact of stereochemistry was evaluated preparing also the corresponding R isomers which, however, exhibited reduced activity. The most interesting compound (99) displayed potent glucose lowering in db/db mice and attenuated increases in heart weight and brown adipose tissue [118] . X-ray chrystallographic studies of the PPAR -LBD complexed with 97 and 99 were performed to gain insight into the molecular mechanism by which these indole derivatives act as SPPAR Ms. The crystal structures revealed that these ligands are bound in the entry-end of the ligand binding pocket at a distance from helix 12 that precludes direct contact with Tyr-473. The acid portion of the (S)-lactate is positioned such that both oxygens are in hydrogen-bonding distance to contact the main chain amide nitrogen of Ser-342. This particular positioning of the acid group allows interactions with the -sheet and helix 3 whose increased stabilization seems to be responsible of the activity of most PPAR partial agonists [120, 121] . Given that fibrates are relatively weak PPAR agonists that possess a good efficacy and tolerability profile, the same scientists sought to combine both features of a SPPAR M and a relatively weak PPAR agonist to generate a new type of PPAR / dual agonist with improved efficacy and safety profile. For this purpose, they prepared the novel series of chiral N-benzyl-indoles (100) in which major chemistry efforts were directed toward the introduction of different substitution patterns at the position of the carboxylic group. This part of the molecule, in fact, proved to be a very productive site for fine-tuning selectivity ratio between the / receptors. Interestingly, the R enantiomers were more potent on PPAR than the corresponding S isomers and their activity generally enhanced increasing the size of the substituents. On the contrary, binding affinity and functional activity towards PPAR were less affected by the stereochemistry of these compounds. The dual agonist (101) demonstrated potent efficacy in lowering both glucose and lipids in multiple animal models with significantly attenuated side effects such as fluid retention and heart weight gain [122] . A further modification of 101, aimed at improving the pharmacokinetic profile, was realized by excising the methylene moiety and directly attaching the phenyl ring to the nitrogen of the indole ring system to yield compound MK-0533 (102) . This optimized indole derivative, having S configuration, was a potent PPAR partial agonist with high selectivity over PPAR that exhibited comparable efficacy to rosiglitazone in vivo and, similar to compound (101), a reduced potential for untoward events [123] . No data were reported for the corresponding R isomer.
Finally, some -substituted arylthioacetic acids are worthy of mention in this section of the review. Pirinixic acid (103) has been established as an experimental PPAR ago-nist with micromolar activity and some inherent PPAR activity [6] . Aliphatic substitution in position to the carboxylic acid head group of pirinixic acid improved both PPAR and, in particular, PPAR activity and led to balanced dual PPAR / agonists in the lower micromolar range. The effects of stereochemistry were investigated preparing the individual R and S enantiomers of some derivatives. The former (104-106) were more potent activators of PPAR and this effect increased with the lengthening of the -alkyl chain. Notably, PPAR activation was merely affected. A very potent PPAR agonist with excellent selectivity over PPAR (107) was obtained by replacing the central pyrimidine ring of 105 by benzene and the amine linker by a larger propane-1,3-diol moiety [124] [125] [126] .
A reverse stereoselectivity was observed for a series of recently reported -(benzothiazol-2-yl)thio-propanoic acids. These compounds, considered as clofibric acid analogues, were basically PPAR agonists with the S isomers more potent than the R counterparts. In the series of optically active ligands, the best findings were obtained with the isomer (108) [127] . 
CONCLUDING REMARKS
The search for new PPAR ligands has undergone some major changes in the last years. The initial development of selective full agonists (fibrates for PPAR , TZDs and Ltyrosine derivatives for PPAR ) has been basically replaced by compounds acting as dual or pan-agonists. PPAR / dual agonists, in fact, are reported for all the classes of drugs covered in this review, whereas pan-agonists are found among the -alkyl-and -alkoxy--phenyl-propanoic acids. Current research lines, however, are targeted at the identification of SPPARMs, namely partial agonists with low potency in PPAR activation but hypoglycemic activity and beneficial effects on lipid levels similar to full agonists. Some promising SPPAR Ms are reported among -substituted aryloxyacetic acid derivatives, even though most drugs belonging to this class show a remarkable PPAR activity as expected from compounds which can be considered as chiral analogs of fibrates. SPPAR Ms and even more interesting dual selective PPAR / modulators are found among -alkoxy--phenyl-propanoic acids which appear as the most versatile class of ligands exhibiting, in fact, also selective PPAR and PPAR agonists, PPAR / dual agonists and pan-agonists.
From a structural standpoint the impressive work accomplished in the last fifteen years has shown that PPARs are characterized by a high degree of stereoselectivity towards several classes of chiral drugs. In particular, PPAR activity is strongly affected from the presence of a stereogenic center close to the acidic function, which represents a polar head group shared by most of current PPAR agonists. Many reports, in fact, have underlined the importance of a correct spacial arrangement of the groups bound to this stereogenic center which plays a crucial role in determining the PPAR binding mode. A clear correlation between the PPAR activity and the S configuration of most ligands has been established. Only for -substituted aryloxyacetic acids (fibrates), the stereoselectivity changes depending on type, size and number of substituents bound to the stereogenic center. For these compounds the S enantiomers are generally preferred except when the chiral center is included into a conformationally constrained ring or is a tetrasubstituted asymmetric carbon. The presence in the literature of some exceptions to this rule, however, should not be overlooked even though it can not be ruled out that, in some cases, the absolute configuration of the enantiomers has not been correctly assigned. The structural characterization by crystallographic methods of complexes formed by PPARs with their ligands turns out to be an essential tool to explain receptor stereoselectivity. These 3D structures provide important information about the ligand/PPAR interactions, giving insights on the residues involved in the ligand binding and ligand-dependent activation of PPAR. In addition, this structural approach opens the way to the rational design of partial or full, and specific or pan-agonists.
Despite the large number of reports dealing with optically active PPAR ligands, only very few of them have been developed as clinical candidates. Even though they were discontinued for safety issues, nevertheless the search for new stereoselective PPAR agonists seems to be a goal to be pursued. The presence of steric constraints, in fact, is able to induce a different stabilization of the receptor active conformation allowing the recruitment of different co-activators and, finally, a possible pharmacological dissociation, for a pair of enantiomers, of therapeutic activity from adverse side effects. In this case, the stereoisomer devoid of toxic effects could be developed even though endowed with less PPAR agonist activity. The potency in PPAR activation, in fact, is not a determinant for the discovery of new agonists as shown by SPPARMs. The levo-isomer of halofenate, known as metaglidasen, is probably the first example of SPPAR M which is in development as a single enantiomer due to its lower ability to inhibit cytochrome P450 2C9 (CYP2C9) compared to the corresponding dextro-isomer. Undoubtedly, the discovery and development of a drug as an individual stereoisomer are more costly and less feasible compared to racemates or achiral drugs, however, some examples suggest that this could be the right way for the identification of safer agonists and modulators of PPARs that still remain an important target in the search for new drugs in the treatment of metabolic diseases. 
